NASDAQ:AVTX

Avalo Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy AVTX

*Your capital is at risk

$18.25

-1.14 (-5.88%)

At Close: Jul 31, 2026

Avalo Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -57.05. In total, the insiders bought 1.15M and sold 333.4K AVTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-57.05
● Buy	1.15M shares
● Sell	333.4K shares
63% Buy Activity Moderate Negative Correlation
Sell Signal High Confidence May 06, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -57.05. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 06, 2026 Sell	Common Stock S-Sale	Varki Paul Chief Legal Officer	Officer	37 375 Value: $706.8K
May 06, 2026 Sell	Common Stock S-Sale	Varki Paul Chief Legal Officer	Officer	5 196 Value: $102.8K
May 06, 2026 Sell	Common Stock S-Sale	Varki Paul Chief Legal Officer	Officer	22 839 Value: $484.5K
May 06, 2026 Sell	Common Stock S-Sale	Varki Paul Chief Legal Officer	Officer	9 253 Value: $210.0K
May 06, 2026 Sell	Common Stock S-Sale	Varki Paul Chief Legal Officer	Officer	400 Value: $9K
May 06, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Sullivan Christopher Ryan Chief Financial Officer	C-Suite Officer	47 000 Value: $377.9K
May 06, 2026 Buy	Common Stock M-Exempt	Sullivan Christopher Ryan Chief Financial Officer	C-Suite Officer	47 000 Value: $377.9K
May 06, 2026 Sell	Common Stock S-Sale	Sullivan Christopher Ryan Chief Financial Officer	C-Suite Officer	13 834 Value: $256.7K
May 06, 2026 Sell	Common Stock S-Sale	Sullivan Christopher Ryan Chief Financial Officer	C-Suite Officer	12 347 Value: $238.1K
May 06, 2026 Sell	Common Stock S-Sale	Sullivan Christopher Ryan Chief Financial Officer	C-Suite Officer	2 700 Value: $56.1K
May 06, 2026 Sell	Common Stock S-Sale	Sullivan Christopher Ryan Chief Financial Officer	C-Suite Officer	9 219 Value: $197.0K
May 06, 2026 Sell	Common Stock S-Sale	Sullivan Christopher Ryan Chief Financial Officer	C-Suite Officer	8 900 Value: $200.9K
May 06, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Doyle Mittie Chief Medical Officer	Officer	77 905 Value: $985.5K
May 06, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Doyle Mittie Chief Medical Officer	Officer	28 650 Value: $230.3K
May 06, 2026 Buy	Common Stock M-Exempt	Doyle Mittie Chief Medical Officer	Officer	28 650 Value: $230.3K
May 06, 2026 Sell	Common Stock S-Sale	Doyle Mittie Chief Medical Officer	Officer	27 538 Value: $496.4K
May 05, 2026 Sell	Common Stock S-Sale	Doyle Mittie Chief Medical Officer	Officer	1 679 Value: $26.9K
May 05, 2026 Buy	Common Stock M-Exempt	Doyle Mittie Chief Medical Officer	Officer	1 000 Value: $12.7K
May 05, 2026 Buy	Common Stock M-Exempt	Doyle Mittie Chief Medical Officer	Officer	679 Value: $5K
May 05, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Doyle Mittie Chief Medical Officer	Officer	1 000 Value: $12.7K
May 05, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Doyle Mittie Chief Medical Officer	Officer	679 Value: $5K
Apr 30, 2026 Sell	Common Stock S-Sale	Sullivan Christopher Ryan Chief Financial Officer	C-Suite Officer	8 457 Value: $111.9K
Apr 29, 2026 Sell	Common Stock S-Sale	Sullivan Christopher Ryan Chief Financial Officer	C-Suite Officer	8 458 Value: $110.7K
Apr 06, 2026 Sell	Common Stock S-Sale	Doyle Mittie Chief Medical Officer	Officer	3 970 Value: $71.5K
Apr 06, 2026 Buy	Common Stock M-Exempt	Doyle Mittie Chief Medical Officer	Officer	3 970 Value: $50.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT AVALO THERAPEUTICS, INC.

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe...

Read Full Profile Here